Guanxinshutong capsule ameliorates cardiac function and architecture following myocardial injury by modulating ventricular remodeling in rats

• Published in: Biomedicine & pharmacotherapy Vol. 130; p. 110527
• Main Authors: Zhu, Jiaqi, Zhou, Huifen, Li, Chang, He, Yu, Pan, Yuming, Shou, Qiyang, Fang, Minsun, Wan, Haitong, Yang, Jiehong
• Format: Journal Article
• Language: English
• Published: France Elsevier Masson SAS 01.10.2020; Elsevier
• Subjects: Angiogenesis; Animals; Drugs, Chinese Herbal - administration & dosage; Drugs, Chinese Herbal - pharmacology; Drugs, Chinese Herbal - therapeutic use; Echocardiography; Electrocardiography; Fibrosis; Gene Expression Regulation - drug effects; Guanxinshutong capsule; Intercellular junction; Intercellular Junctions - drug effects; Male; Myocardial fibrosis; Myocardial Infarction - diagnostic imaging; Myocardial Infarction - drug therapy; Myocardial Infarction - pathology; Myocardial injury; Myocardium - pathology; Myocytes, Cardiac - drug effects; Myocytes, Cardiac - pathology; Rats; Rats, Sprague-Dawley; Ventricular Dysfunction, Left - drug therapy; Ventricular remodeling; Ventricular Remodeling - drug effects; GXST-MD; Cx-43; SD; Angiogenesis; Control; LVPWs; MI; Guanxinshutong capsule; HPLC; WHO; Intercellular junction; Myocardial fibrosis; Ventricular remodeling; LVPWd; N-cad; GXST-HD; GXST-LD; IL-6; VEGFA; WGA; GXST; TNF-α; MMP-2; PDGF; TAC; Model; TGF-β1; VR; IVSd; HE; MMP-9; ELISA; Myocardial injury
• ISSN: 0753-3322; 1950-6007
• DOI: 10.1016/j.biopha.2020.110527

[Display omitted] •The role of Guanxinshutong capsule in myocardial injury is investigated.•Myocardial injury-transverse aortic constriction causes ventricular remodeling.•Guanxinshutong capsule ameliorates cardiac hypertrophy and fibrosis in rats.•This study provides a guidance for the treatment of myocardial injury in clinic. Guanxinshutong capsule (GXST), which consists of five traditional Chinese medicines, has been used for a long time in China for the treatment of cardiovascular diseases, such as coronary artery disease and myocardial infarction. However, the effects on GXST on myocardial injury (MI) have not been studied in detail. In these experiments, we found that GXST administration decreased MI-associated ventricular remodeling (VR) with a reduction in interventricular septal thickness in diastole (IVSd), left ventricular posterior wall diameter in systole (LVPWs), and left ventricular posterior wall diameter in diastole (LVPWd) to ameliorate cardiac function and architecture, as measured by echocardiography. Furthermore, histological analysis showed that GXST could ameliorate pathological alterations in the myocardium. And Sirius red staining, wheat germ agglutinin staining and inflammation-related immunohistochemistry results showed that GXST ameliorated the fibrosis areas, cardiac hypertrophy and inflammation (IL-6 and TNF-α). In addition, GXST upregulated intercellular junction proteins (N-cad and Cx-43) and downregulated the angiogenesis-related proteins (PDGF and VEGFA), myocardial fibrosis-related proteins (TGF-β1), and matrix metalloproteinase (MMP-2 and MMP-9). We also found that GXST medium-dose group (1 g/kg/d) dosage was the most efficacious. In conclusion, GXST protected cardiac tissues against MI by reducing VR, thus indicating the potential application of GXST in the treatment of MI.